Annual sales up 10% for AptarGroup

CRYSTAL LAKE - AptarGroup Inc. reported sales increased 10% to $3.23 billion in the 2021 fiscal year ended Dec. 31, compared to $2.93 billion in the prior year.

Core sales, excluding the impacts from changes in currency exchange rates and acquisitions, increased 7%.

For the full year, Aptar's reported earnings per share were $3.61, an increase of 12%, compared to $3.21 reported a year ago. Current year adjusted earnings per share, excluding restructuring charges, acquisition costs and the unrealized gain on an equity investment, were $3.88 and increased 4% from prior year adjusted earnings per share, the company said.

Aptar is a global supplier in drug delivery and consumer dispensing products, as well as provides active material science solutions and services.

"Each of our segments grew in the (fourth) quarter, reflecting strong demand for our innovative solutions across our various end markets and pricing actions to pass through increased raw material and other input costs," said Stephan B. Tanda, president and CEO.

Aptar's Pharma segment grew solidly in the quarter. Demand for elastomeric components for vaccines and other injected medicines continued to be strong and sales to the consumer health care market grew, including solutions for nasal decongestants used to treat cough and cold symptoms, the company said.